Federated Hermes’s Spyre Therapeutics SYRE Stock Holding History

Federated Hermes’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.63M	Buy	+85,950	New	+$6.27M	0.01%	764
2022 Q4	–	Sell	-77	Closed	-$1K	–	2280
2022 Q3	$1K	Hold	77	–	–	﹤0.01%	2081
2022 Q2	$1K	Buy	+77	New	+$2.7K	﹤0.01%	2081
2020 Q4	–	Sell	-15	Closed	-$3K	–	2325
2020 Q3	$3K	Hold	15	–	–	﹤0.01%	2076
2020 Q2	$3K	Buy	+15	New	+$2.86K	﹤0.01%	2059
2019 Q1	–	Sell	-20	Closed	-$4K	–	2228
2018 Q4	$4K	Sell	20 -32	-62%	-$6.79K	﹤0.01%	2017
2018 Q3	$12K	Sell	52 -9	-15%	-$2.1K	﹤0.01%	1928
2018 Q2	$16K	Buy	61 +30	+97%	+$7.38K	﹤0.01%	1837
2018 Q1	$8K	Buy	+31	New	+$5.6K	﹤0.01%	1911
2017 Q3	–	Sell	-10	Closed	-$1K	–	2190
2017 Q2	$1K	Buy	+10	New	+$1.38K	﹤0.01%	2098

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Federated Hermes's SYRE Position: Q2 2026 in Review

Federated Hermes opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 85,950 shares worth $7.63M. The stake represents 0.01% of the portfolio and ranks #764 among its holdings. This is a return to the name: Federated Hermes previously reported a position in SYRE as recently as Q3 2022.

Federated Hermes first reported a position in SYRE in Q2 2017 and has held it in 10 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

Federated Hermes held 85,950 shares of Spyre Therapeutics worth $7.63M as of Q2 2026.
Spyre Therapeutics was a new Federated Hermes position in Q2 2026.
Spyre Therapeutics made up 0.01% of Federated Hermes's portfolio in Q2 2026, its #764 holding.
Federated Hermes first reported a position in Spyre Therapeutics in Q2 2017 and has held it in 10 quarters since.
266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.